
Okeiro
Innovative solutions for better care and faster drug development.
Date | Investors | Amount | Round |
---|---|---|---|
* | €10.0m | Early VC | |
Total Funding | 000k |
Related Content
Okeiro, formerly known as Predict4Health, is a precision medicine company founded in 2023 by a team of experts in medicine, data science, and artificial intelligence, including CEO Pierrick Arnal. The company's technology originates from 20 years of research by the Paris Transplant Group, which developed the first universal predictive algorithm for transplantation in 2018. This research led to the founding of Cibiltech in 2019, which was later acquired by Predict4Health in 2023 to continue the project. In April 2025, the company rebranded to Okeiro, a name inspired by the Greek word 'Kairos' (critical moment), and secured €10 million in a Series A funding round to accelerate its international deployment.
The Paris-based firm develops an AI-powered clinical decision support platform designed to prevent organ failure in transplant patients and individuals with advanced chronic diseases affecting the kidneys, lungs, heart, and liver. Its core technology, the iBox algorithm, is a predictive model marked as a medical device and qualified by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) as a surrogate endpoint. This algorithm integrates multiple data points, including biological, immunological, and clinical parameters, to accurately predict graft survival at three, five, and seven years post-transplant.
Okeiro operates on a multi-faceted business model, serving two primary client types. For healthcare professionals and hospitals, the company provides a platform that offers a clear overview of patient data, enabling early detection of complications and proactive treatment adjustments. The technology is already implemented in French hospitals and has achieved national reimbursement status from the French National Health Insurance. For pharmaceutical companies, the iBox algorithm accelerates clinical trials by providing early, reliable predictions of long-term graft survival, which can facilitate earlier market access for new drugs. The company is conducting randomized clinical trials across 16 hospitals in six countries to further demonstrate its technology's effectiveness.
Keywords: Okeiro, Predict4health, precision medicine, organ transplantation, chronic disease monitoring, AI in healthcare, clinical decision support, graft rejection, predictive algorithms, iBox algorithm, digital biomarkers, medical device, surrogate endpoint, Pierrick Arnal, medtech, remote patient monitoring, kidney failure, health-tech, clinical trial acceleration, transplant medicine